Last reviewed · How we verify
exogenous surfactant
At a glance
| Generic name | exogenous surfactant |
|---|---|
| Also known as | poractantalf, beractant |
| Sponsor | Ege University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- SHAPE Pilot Trial: Skin Health and Allergy Prevention Exposure (NA)
- EXTERNAL NEGATIVE PRESSURE DURING LISA (NA)
- Lung UltrasouNd Guided Surfactant Therapy in Preterm Infants (LUNG Study) (NA)
- Examination of Lacrimal Sac and Nasal Mucosa Preparations Taken in Dacryocystorhinostomy Surgery of Patients With Nasolacrimal Duct Obstruction and Comparison of Clinical Groups With Each Other
- A Pharmacokinetic Study of Polymyxin B in Healthy Subjects and Subjects With Renal Insufficiency (PHASE1)
- REspiratory MEchanics for Delivering Individualised Exogenous Surfactant (NA)
- Role and Molecular Mechanism of Farnesoid X Receptor(FXR) and RIPK3 in the Formation of Acute Respiratory Distress Syndrome in Neonates (NA)
- Exogenous Surfactant in Very Preterm Neonates in Prevention of Bronchopulmonary Dysplasia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- exogenous surfactant CI brief — competitive landscape report
- exogenous surfactant updates RSS · CI watch RSS
- Ege University portfolio CI